Abstract
Premature ejaculation (PE) is the most common male sexual problem worldwide affecting 22-38% of men. It has a significant morbidity both on patients and their partners, causing distress, anxiety and relationship difficulties. The mainstay of treatment is a combined approach using behavioural therapies and non-licensed medication such as topical anaesthetic preparations, selective serotonin re-uptake inhibitors and phosphodiesterase-5 inhibitors. In recent years, there has been a greater emphasis placed on researching novel treatments and exploring the on-demand use of current preparations. This review provides an overview of current accepted treatments and emerging agents for the use in PE.
MeSH terms
-
Administration, Oral
-
Administration, Topical
-
Anesthetics, Combined / therapeutic use
-
Anesthetics, Local / administration & dosage
-
Benzylamines / administration & dosage
-
Benzylamines / therapeutic use
-
Ejaculation*
-
Enzyme Inhibitors / administration & dosage
-
Enzyme Inhibitors / therapeutic use
-
Humans
-
Lidocaine / therapeutic use
-
Lidocaine, Prilocaine Drug Combination
-
Male
-
Naphthalenes / administration & dosage
-
Naphthalenes / therapeutic use
-
Phosphodiesterase 5 Inhibitors
-
Prilocaine / therapeutic use
-
Selective Serotonin Reuptake Inhibitors / administration & dosage
-
Selective Serotonin Reuptake Inhibitors / therapeutic use
-
Sexual Dysfunction, Physiological / drug therapy*
Substances
-
Anesthetics, Combined
-
Anesthetics, Local
-
Benzylamines
-
Enzyme Inhibitors
-
Lidocaine, Prilocaine Drug Combination
-
Naphthalenes
-
Phosphodiesterase 5 Inhibitors
-
Serotonin Uptake Inhibitors
-
Prilocaine
-
Lidocaine
-
dapoxetine